APOLLOHOSP.NS · Intrinsic value
Is Apollo Hospitals Enterprise Limited (APOLLOHOSP.NS) overvalued or undervalued?
Apollo Hospitals Enterprise Limited (APOLLOHOSP.NS) trades at the delayed market price of ₹7,700.00 a share. That price already implies revenue growth of more than 25%/yr. TickerWorth's fair value is ₹3,394.51 a share (127% above fair value), as of Oct 19, 2026. It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
Is APOLLOHOSP.NS overvalued?
- Fair value
- ₹3,394.51
- Market price
- ₹7,700.00
- Downside to fair value
- 55.9%
- Verdict
- 127% above fair value
Reverse DCF: Today's price implies revenue growth of more than 25%/yr. Above about 25% a year the reverse-DCF stops being informative. It solves for revenue growth alone — holding margins, capital intensity and the forecast horizon fixed — so a price well above our cash-flow model's value has nowhere to go but growth, and the solver returns a rate the model can't reconcile. Read it as "the price implies growth we can't justify", not as a forecast.
What is APOLLOHOSP.NS's TickerWorth Score?
Scores lower than almost every company we compare it with
Compared with Healthcare companies in India
Its strongest point: growing quickly. Its weakest: profitability is weak.
- Value · 37 of 100
Cheaper than 37% of Healthcare companies in India
- Price vs worth · 5 of 100
- Quality · 10 of 100
More profitable than 10% of Healthcare companies in India
- Financial health · 17 of 100
Financially stronger than 17% of Healthcare companies in India
- Growth · 65 of 100
Growing faster than 65% of Healthcare companies in India
- Momentum · 48 of 100
Outperformed 48% of Healthcare companies in India over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
APOLLOHOSP.NS DCF valuation: what the price assumes
At a recent price of ₹7,700, Apollo Hospitals Enterprise Limited (APOLLOHOSP.NS) trades 127% above TickerWorth's blended fair value of ₹3,395 per share — a discounted-cash-flow model cross-checked against peer multiples and asset value — meaning the market currently prices APOLLOHOSP.NS overvalued vs our estimate of what the business is intrinsically worth. Our fair value sits below the market, an implied -55.9% move to close the gap if the business performs in line with our assumptions. This is an educational model, not a price target or a recommendation — the value moves with the inputs, which you can test yourself using the WACC slider below.
Read the full reasoning
The valuation discounts Apollo Hospitals Enterprise Limited's projected free cash flows at a weighted-average cost of capital (WACC) of 9.6%, with a long-run terminal growth rate of 2.5%. About 74% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — APOLLOHOSP.NS would need sustained revenue growth of more than 25%/yr to justify today's price, against about 12.1% a year compounded in our base case. We don't quote a precise figure here, because past about 25% a year the reverse-DCF stops being informative: it solves for revenue growth alone, holding margins, capital intensity and the forecast horizon fixed, so a price well above our fair value has nowhere to go but growth. The honest reading is that the price implies growth this model can't reconcile — not that we forecast it.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, APOLLOHOSP.NS's modeled DCF value ranges from about ₹2,468 to ₹5,348 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Apollo Hospitals Enterprise Limited would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of APOLLOHOSP.NS's intrinsic value. Figures update as new filings and prices come in.
Every input behind APOLLOHOSP.NS's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | ₹264,299,000,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 12.2% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 21% → 16% → 12% → 8% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.2% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 1.00 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 144M |
| Market priceLast known price · as of 2026-10-19 18:39 UTC | ₹7,700 |
Change APOLLOHOSP.NS's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Apollo Hospitals Enterprise Limited do?
What does it do?
Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments. It operates in the Medical Care Facilities industry (Healthcare sector), headquartered in India. The company employs roughly 44,008 people.
How does it make money?
The business turns 264.3B in annual revenue into profit. Out of every $100 of sales, about $12 is left as operating profit (operating margin of 12.2%), after a 35% gross margin on the products/services it sells. After all costs, taxes and interest, 7.9% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (0.9× equity), and is currently profitable.
APOLLOHOSP.NS insider trading
Insider filings are available for US-listed companies only.
Common questions
What is APOLLOHOSP.NS's intrinsic value?
TickerWorth's blended fair value for Apollo Hospitals Enterprise Limited (APOLLOHOSP.NS) is ₹3,395 per share, versus a market price of ₹7,700 (127% above fair value).
Is APOLLOHOSP.NS overvalued or undervalued?
On our blended fair value APOLLOHOSP.NS looks overvalued vs fair value at ₹7,700. This is an educational estimate, not advice.
What discount rate is used for APOLLOHOSP.NS?
A WACC of 9.6% and a terminal growth rate of 2.5%.
Is Apollo Hospitals Enterprise stock undervalued?
TickerWorth's fair value for Apollo Hospitals Enterprise Limited (APOLLOHOSP.NS) is ₹3,394.51 against a market price of ₹7,700.00. Our read: 127% above fair value. This is a model estimate, not investment advice.
Apollo Hospitals Enterprise (APOLLOHOSP.NS) DCF valuation and fair value
Our fair value for Apollo Hospitals Enterprise Limited (APOLLOHOSP.NS) is ₹3,394.51, built on a 9.6% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Apollo Hospitals Enterprise stock?
Today's price implies revenue growth of more than 25%/yr. Above about 25% a year the reverse-DCF stops being informative. It solves for revenue growth alone — holding margins, capital intensity and the forecast horizon fixed — so a price well above our cash-flow model's value has nowhere to go but growth, and the solver returns a rate the model can't reconcile. Read it as "the price implies growth we can't justify", not as a forecast. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of ₹7,700.00. A model estimate, not investment advice.
Apollo Hospitals Enterprise (APOLLOHOSP.NS) insider trading
We have no recent SEC Form 4 insider filings on file for Apollo Hospitals Enterprise Limited (APOLLOHOSP.NS). Form 4 covers US-listed companies only.
Stocks below our fair value instead
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.